Anagenix and CytoSolve Build an Integrative Systems Architecture Explaining Kiwifruit-Derived Supplement Synergy on Gut Motility Mechanisms

Anagenix Group develops wholefood-based nutritional supplements, including Actazin™ and Livaux™, derived from green and gold kiwifruit, respectively. Their products are supported by clinical and experimental evidence in digestive health, with a focus on translating food-based bioactives into measurable physiological benefits.

Challenge

Clinical and experimental studies indicate that Actazin™ and Livaux™ positively impact digestive health, yet the molecular mechanisms driving these effects—both for individual ingredients and their combinations—were not fully characterized. Gut motility is regulated by multiple interacting biological systems, and conventional approaches often struggle to connect multi-ingredient supplement composition to system-level physiological outcomes.

To enable rational formulation, dosing, and mechanistic substantiation, Anagenix needed a comprehensive, testable systems architecture that could integrate the molecular pathways governing gut motility and evaluate potential synergy across multiple bioactive compounds.

How CytoSolve Helped

CytoSolve supported Anagenix by transforming a broad evidence base into a mechanistic, integrated in silico model of gut motility:

  • Systematic Literature Review to Define Mechanism Space
    A structured review identified molecular pathways implicated in gut motility and the biological processes most consistently supported by published evidence.
  • Pathway-to-Model Conversion with Validation
    The relevant gut motility pathways were translated into individual mathematical models, each validated prior to integration to ensure mechanistic and quantitative integrity.
  • Dynamic Model Integration Using CytoSolve® Systems Architecture
    CytoSolve enabled the plurality of validated pathway models to be integrated into an integrative gut motility model, capturing interactions and feedback across systems rather than treating mechanisms independently.
  • In Silico Testing of Real-World Combinations and Doses
    The complete set of bioactive molecules at recommended dose levels was tested computationally to evaluate synergy and predict multi-pathway impact.

Key Benefits Realized

  • Unified Mechanistic Explanation for Multi-Ingredient Effects
    Converted fragmented pathway evidence into a single integrative model linking ingredient bioactives to gut motility biology.
  • Synergy Quantification Across Core Biological Systems
    Demonstrated system-level synergy consistent with enhanced motility through coordinated modulation of multiple mechanisms.
  • Actionable, Evidence-Grounded Framework for Formulation Strategy
    Provided a reproducible architecture to explore ingredient interactions, dose logic, and combined effects without relying on trial-and-error alone.
  • Mechanism-Based Differentiation for Digestive Health Claims
    Enabled mechanistic substantiation by connecting supplement bioactives to validated molecular pathways governing motility outcomes.

Outcome

Using CytoSolve’s computational systems biology platform, Anagenix developed an integrative in silico systems architecture of gut motility derived from validated molecular pathway models identified through systematic literature review. The results highlighted three major biological systems governing gut motility—inflammation, mucus production, and fecal bulking—and showed that Actazin™ bioactive compounds synergistically enhance gut motility by reducing inflammation, increasing mucus production, and increasing expression of PYY and GLP-1, which in turn increase gut transit time and facilitate fecal bulking. This work established a scalable, mechanistic foundation for understanding and optimizing wholefood-based digestive health supplements, individually and in combination.